Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab with or without methotrexate for hidradenitis suppurativa
2019-002959-42Phase 3Active
- Sponsor
- Ramsay Santé
- Start
- Nov 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of adalimumab and methotrexate in hidradenitis suppurativa (HS) (2 arms), sponsored by Ramsay Santé. Primary endpoint: Clinical response rate at Month 6. Started Nov 2019; status: active.
02
Drugs
adalimumabmethotrexate
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on 2019-002959-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002959-42.